| |
CEE + MPA trial
|
CEE trial
|
|---|
| |
Cases
|
Controls
|
P-value*
|
Cases
|
Controls
|
P-value*
|
|---|
|
N
|
348
|
348
| |
235
|
235
| |
|
Age†
|
64.32 ± 6.85
|
64.33 ± 6.82
|
0.98
|
64.5 ± 7.11
|
64.49 ± 7.06
|
0.97
|
|
BMI
|
29.33 ± 5.56
|
28.46 ± 5.69
|
0.04
|
31.46 ± 5.98
|
29.32 ± 5.70
|
<0.01
|
|
Gail model five-year risk score (%)
|
1.85 ± 0.89
|
1.72 ± 0.84
|
0.05
|
1.84 ± 1.65
|
1.36 ± 0.90
|
0.08
|
|
Race (%)†
| | |
0.99
| | |
0.98
|
|
White
|
305 (87.6)
|
305 (87.6)
| |
184 (78.3)
|
184 (78.3)
|
|
Black
|
21 (6.0)
|
21 (6.0)
| |
36 (15.3)
|
35 (14.9)
|
|
Other
|
22 (6.3)
|
22 (6.3)
| |
15 (6.4)
|
16 (6.8)
|
|
Smoking (%)
| | |
0.11
| | |
0.72
|
|
Never
|
158 (46.1)
|
186 (54.1)
| |
129 (55.1)
|
126 (53.6)
|
|
Past
|
155 (45.2)
|
131 (38.1)
| |
87 (37.2)
|
86 (36.6)
|
|
Current
|
30 (8.7)
|
27 (7.8)
| |
18 (7.7)
|
23 (9.8)
|
|
Family history of breast cancer (%)
| | |
0.006
| | |
0.23
|
|
Yes
|
79 (24.0)
|
50 (15.2)
|
52 (23.5)
|
42 (18.5)
|
|
No
|
250 (76.0)
|
280 (84.8)
| |
169 (76.5)
|
185 (81.5)
| |
- *P-values are significance levels from Student’s t-test and chi-square tests of no difference between cases and controls for continuous and categorical variables.
- †Matching variables in control selection. BMI, body mass index; CEE, conjugated equine estrogens; MPA, medroxyprogesterone acetate.
